ArticleVeterinary research2026
African swine fever virus pC147L inhibits retinoic acid-inducible gene I-like receptors pathway via targeting MAVS-TRAF6 complex.
Article in Veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
African swine fever virus (ASFV) suppresses the host's innate immunity by interfering with pattern recognition receptors (PRRs) signaling pathways; however, the molecular mechanisms by which it inhibits PRR signaling remain poorly characterized. This study aimed to identify the ASFV-encoded protein pC147L. The pC147L, a subunit of the viral RNA polymerase, acts as a potent inhibitor of the Retinoic Acid-inducible Gene I (RIG-I)-like receptors (RLRs) pathway, which mediates the detection of viral double-stranded RNA. We used quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blot assays, and demonstrated that pC147L specifically blocked RLRs-mediated interferon-β (IFN-β) production without affecting other antiviral pathways, such as TLR3 or cGAS-STING pathways. Mechanistically, pC147L targeted mitochondrial antiviral signaling protein (MAVS), the central adaptor of RLR signaling pathway, to disrupt downstream signal transduction. Co-immunoprecipitation assays revealed that pC147L physically interacted with both MAVS and TRAF6, preventing the formation of the MAVS-TRAF6 complex and subsequent TBK1 recruitment required for MAVS signalosome assembly. Furthermore, the overexpression and knockdown experiments demonstrated that pC147L enhanced ASFV replication by suppressing the type I IFN response in porcine alveolar macrophage (PAM) cells. Collectively, our findings revealed a positive role of pC147L during ASFV infection by promoting viral replication through suppressing innate immune response, presenting it as a potential target for vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.